• Angiotensin III: Advanced Applications in RAAS Research

  2026-05-06

  Angiotensin III (human, mouse) empowers high-fidelity modeling of RAAS-mediated cardiovascular and neuroendocrine pathways, with peer-reviewed evidence linking its activity to both classical and emerging disease contexts. This guide translates recent mechanistic insights and workflow best practices into actionable protocols—optimizing the impact of APExBIO’s validated peptide in complex experimental systems.

• Pharmacokinetic Variability of CSBTA Alkaloids in MASH: Insi

  2026-05-05

  This study systematically characterizes the pharmacokinetics and tissue distribution of Corydalis saxicola Bunting total alkaloids (CSBTA) in mouse models of metabolic dysfunction-associated steatohepatitis (MASH) induced by a high-fat, high-cholesterol diet. The research highlights how pathological changes alter drug metabolizing enzymes and transporters, informing dosing strategies for MASLD/MASH therapies.

• Genistein in Mechanotransduction: Bridging Tyrosine Kinase I

  2026-05-05

  Explore how Genistein, a selective tyrosine kinase inhibitor, advances cancer chemoprevention by modulating cytoskeleton-dependent autophagy. This in-depth analysis reveals unique mechanistic insights and protocol guidance not found in standard workflows.

• Risedronate Sodium: FPP Synthase Inhibitor in Translational

  2026-05-04

  Risedronate Sodium, a potent FPP synthase inhibitor, is transforming bone metabolism and cancer research through advanced delivery methods and robust in vitro and in vivo models. This article details experimental workflows, troubleshooting, and innovative protocol enhancements enabled by APExBIO's Risedronate Sodium, with actionable insights from recent microneedle patch research.

• Pharmacokinetics of Corydalis saxicola Alkaloids in MASH Mic

  2026-05-04

  This study systematically analyzes the pharmacokinetic variability of Corydalis saxicola Bunting total alkaloids (CSBTA) in a high-fat, high-cholesterol diet (HFHCD)-induced mouse model of metabolic dysfunction-associated steatohepatitis (MASH). By integrating tissue distribution, transporter activity, and metabolic enzyme expression, the research reveals disease-state-dependent changes in drug exposure, with implications for rationalizing clinical dosing in MASLD/MASH.

• Basic Protein Native PAGE Gel Kit: Native-State Protein Elec

  2026-05-03

  The Basic Protein Native PAGE Gel Preparation and Electrophoresis Kit (PI ≤ 7.0) enables native protein gel electrophoresis for acidic proteins, preserving biological activity and providing high-resolution separation. The kit, manufactured by APExBIO, delivers reliable results for protein purification and identification without the use of denaturants. Performance benchmarks and workflow parameters are supported by both product specifications and peer-reviewed literature.

• Indometacin Sodium: Optimizing Inflammation and Differentiat

  2026-05-02

  Indometacin Sodium Trihydrate (APExBIO) goes beyond conventional COX inhibition, empowering advanced inflammation and neuroregeneration workflows through robust, reproducible assay performance. This guide translates clinical and preclinical evidence into actionable laboratory protocols, troubleshooting strategies, and comparative insights for translational research.

• Advancing In Vitro Evaluation of Cancer Drug Responses

  2026-05-01

  Schwartz's dissertation introduces a nuanced in vitro framework for distinguishing between proliferative arrest and cell death in anti-cancer drug evaluation. This approach sharpens the interpretation of drug response assays, offering deeper insights for translational cancer biology.

• PERK-JAK1–STAT3 Axis Drives Pyroptosis in Disc Degeneration

  2026-05-01

  This study elucidates how sustained endoplasmic reticulum stress (ERS) accelerates pyroptosis in nucleus pulposus cells via PERK-dependent JAK1–STAT3 signaling, establishing a mechanistic link to intervertebral disc degeneration. The findings highlight therapeutic potential in targeting the PERK/eIF2α/ATF4-JAK1–STAT3 axis to mitigate inflammation-driven disc pathology.

• EPZ-6438 in Combination Epigenetic Cancer Therapy: Mechanism

  2026-04-30

  Explore how EPZ-6438, a potent EZH2 inhibitor, drives breakthroughs in epigenetic cancer research and combinational therapy strategies. Uncover unique mechanistic insights, practical assay recommendations, and data-driven perspectives distinct from prior coverage.

• EdU Imaging Kits (488): Transforming S-Phase Analysis in Onc

  2026-04-30

  This thought-leadership article explores the mechanistic, translational, and strategic impact of EdU Imaging Kits (488) for quantifying S-phase DNA synthesis, with a focus on liver cancer research and the emerging biomarker HAUS1. Drawing on recent literature and workflow evidence, we highlight how APExBIO’s click chemistry platform advances cell proliferation assays, supports high-integrity imaging, and accelerates biomarker-driven discovery. Protocol guidance, competitive insights, and a forward-looking perspective are included.

• PKM2 Inhibitor (Compound 3k): Redefining Selective Cancer Me

  2026-04-29

  Explore how PKM2 inhibitor (compound 3k) advances selective cancer cell metabolism disruption and illuminates the metabolic-immune interface. This article provides a deep scientific analysis and protocol guidance, distinguishing it from existing workflow- and scenario-focused resources.

• Zosuquidar (LY335979): Precision P-gp Inhibition in MDR Canc

  2026-04-29

  Zosuquidar (LY335979) 3HCl empowers oncology researchers to reverse multidrug resistance by selectively inhibiting P-glycoprotein efflux pumps. This guide details experimental workflows, troubleshooting strategies, and protocol parameters—bridging bench evidence and clinical translation for robust drug sensitization in cancer models.

• Angiotensin II in Vascular Remodeling & Hypertrophy Research

  2026-04-28

  Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) is the gold-standard experimental catalyst for dissecting vascular smooth muscle cell hypertrophy and cardiovascular remodeling. This guide unpacks evidence-backed workflows, advanced troubleshooting, and unique mechanistic insights, leveraging APExBIO’s rigorously validated peptide.

• Saquinavir in HIV Research: Advanced Permeability Modeling a

  2026-04-28

  Discover how Saquinavir, a leading HIV protease inhibitor, enables advanced drug permeability modeling and translational research beyond conventional antiretroviral workflows. Explore unique protocol insights and real-world applications informed by cutting-edge biomimetic chromatography.

15829 records 1/1056 page Next 12345 下5页 Last page